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Joseph Matthew Ladowski 
CHARACTERIZATION OF ANTIBODY BINDING TO SWINE LEUKOCYTE 
ANTIGEN CLASS II  
Though the elimination of carbohydrate xenoantigens has reduced the 
antibody barrier to clinical xenotransplantation, identification of additional targets 
of rejection could further increase the immunologic compatibility of pig tissues 
with humans.  Many patients in need of organ transplantation have antibodies to 
proteins encoded by the human major histocompatibility complex (MHC) which 
have high similarity to their swine homologs.  The goal of this thesis was to 
determine if the class II genes of the swine MHC can bind human antibodies.  
 To characterize antibody binding effect to class II swine leukocyte 
antigens (SLA), a constitutively positive SLA class II cell was created through 
transfection with the human class II transactivator (CIITA).  Cells expressing only 
SLA-DR or SLA-DQ were also created using the CRISPR/Cas9 gene knockout 
tools.  These various lines were incubated with human sera and tested for 
binding to IgM and IgG in a flow cytometry crossmatch (FCXM).  
The results demonstrate reliable antibody binding to each of the SLA class 
II –DR and –DQ derivatives. A two-way paired t-test revealed statistical 
difference in total sera binding between to the DR(+)DQ(+) and DR(-)DQ(-) 
clones for IgG (p = 0.0059) but not IgM (p = 0.2460). Looking at the subset of 
individuals with and without anti-HLA class II sensitization, statistical difference 
was noted for IgG (p = 0.0229) but not IgM (p = 0.3045). Examining further the 
role of DR(+) vs DQ(+), statistical analysis revealed difference in the DR(+)DQ(-) 
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vs. the DR(-)DQ(+) FCXM (p = 0.0099), the DR(+)DQ(-) vs. the DR(+)DQ(+) 
FCXM (p = 0.0192), and the DR(-)DQ(-) parent vs. DR(+)DQ(+) FCXM (p = 
0.0329). No difference was found in the DR(-)DQ(+) vs. DR(+)DQ(+) FCXM (p = 
0.1601).  
The results of this project suggest that SLA class II, specifically SLA-DQ, 
could be a target of antibody binding and cross-reactive anti-HLA class II 
antibodies may be capable of binding SLA class II.  
 
 
A. Joseph Tector MD, PhD, Chair
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INTRODUCTION 
Transplant Organ Shortage 
As of March, 2016 there are over 121,000 patients in need of a lifesaving 
organ transplant. Of these patients, over 100,000 await a kidney, and 12 of those 
potential kidney recipients die each day (Organ Donation and Transplantation 
Statistics, 2015). This list does not include the necessity for pancreatic islets, eye 
tissue, red blood cells, skin tissue, and neuronal cells as well. To address the 
discrepancy between organ donors and potential recipients, xenotransplantation, 
the use of animals as organ donors, could be a possible supply for organs. 
Originally it was thought that Non-Human Primates (NHPs), such as baboons 
and chimpanzees, would be a suitable donor but ethical concerns and the 
potential risk that a NHP-confined virus could potentially infect human cells make 
pigs a more suitable source. Additionally, pigs have a shorter gestational period 
and time to maturity, similar physiologic size for kidneys transplants, larger litters, 
and cost less to raise and maintain (Cooper, 2012).  
Barriers to Xenotransplantation 
The original Wild-Type (WT) xenografts failed rapidly due to hyperacute 
rejection mediated by recipient preformed antibodies to some of the donor 
xenograft carbohydrates. The first and most well-known of these carbohydrates 
is Galα1-3Gal β 1-4GlcNAc-R commonly referred to as (αGal) (Galili, 1993). 
Disruption of α-1,3-galactosyltransferase, the enzyme responsible for 
synthesizing αGal epitopes within the Golgi apparatus, resulted in significantly 
decreased xenoantibody binding, but acute rejection remained a problem (Chen, 
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et al., 2005). The disruption of two other enzymes is theorized to further 
decrease the xenoantigen barrier, Cytidine-Monophosphate-Acetylneuraminic 
Acid Hydroxylase (CMAH) and β1,4N-acetylgalactosaminyl Transferase 
(β4GalNT2). Mutation of CMAH and βGalNT2 on an αGal-deficient background 
diminished antibody binding on Peripheral Blood Mononuclear Cells (PBMCs) to 
levels that may be considered clinically acceptable. Unfortunately a group of 
individuals remain with persistently elevated antibody binding (Estrada, et al., 
2015). Given that the MHC genes of humans and swine are highly similar and 
the fact that many humans have antibodies to non-self human MHC, it is 
theorized this residual binding could be to proteins encoded by the swine MHC.  
The Major Histocompatibility Complex (MHC) 
The classical MHC genes, responsible for presenting peptide antigens to 
T-cells, are commonly divided into two classes of relevance to transplantation: 
class I and II. The human versions are referred to as Human Leukocyte Antigens 
(HLA) and the porcine is 
referenced as Swine Leukocyte 
Antigens (SLA). Generally MHC 
class I presents endogenous 
peptides, commonly self-proteins 
or invasive viral particles, and 
MHC class II presents exogenous 
peptides (Parham, 2005). 
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MHC class I is present on the majority of nucleated cells as a heterodimer 
composed of the class I heavy chain bound to the protein B2-microglobulin (β2m) 
(Figure 1) (van Endert, 1999). While class I is found on nearly every cell, 
constitutive expression of MHC class II is typically considered to be restricted to 
professional antigen-presenting cells (APCs). Work by Daar et al has shown that 
this model might not be accurate and that class II expression can be found on 
multiple organ systems (Daar, Fuggle, Fabre, Ting, & Morris, 1984). In addition, 
stimuli such as Interferon-γ (IFN-γ) can drive the expression of class II MHC 
genes by non APC (Steimle, Otten, Zuffarey, & Mach, 1993). 
MHC Class II 
Class II molecules, like class I, are heterodimers constructed in the 
Endoplasmic Reticulum (ER) with a binding pocket capable of binding longer 
peptides than the MHC class I binding pocket (13-25 compared to class I’s 8-10 
amino acids). In the ER, the newly synthesized alpha and beta chains of MHC 
class II bind to a third chain, the invariant chain (Guagliardi, et al., 1990). The 
invariant chain assists class II protein folding in the ER (Cresswell, 1994) and 
blocks the class II binding pocket to inhibit peptide loading of class II.  The 
invariant chain also directs trafficking of class II molecules to the endocytic 
pathway (Riberdy, Newcomb, Surman, Barbosat, & Cresswell, 1992) where it is 
cleaved by proteases such as cathepsin S, leaving a small fragment named the 
class II-associated Invariant-Chain Peptide (CLIP) still bound to the class II 
binding pocket. CLIP can then be removed by a specific class II glycoprotein, 
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HLA-DM, and the class II binding pocket is then capable of sampling endocytic 
vesicle antigens (Denzin & Cresswell, 1995) (Kropshofer, et al., 1996).  
Role of CIITA in MHC Class II Creation 
Transcription of the class II proteins is controlled by presence of the class 
II transactivator (CIITA), an “on/off switch” for class II creation. Multiple 
promoters, leading to multiple CIITA transcripts, regulate CIITA. These promoters 
are selectively activated in various cell types and lead to either inducible or 
constitutive expression. IFN-γ has been shown to induce class II expression 
through CIITA via the Janus kinase (Jak)-Stat pathway (Lee & Benveniste, 
1996). Binding of IFN-y to its cell-surface receptor activates Janus kinase 1 
(Jak1) and Jak2, allowing the Jak molecules to phosphorylate Stat1, a 
transcription factor located in the cytoplasm which when activated translocates to 
the nucleus and activates the IFN-γ-responsive promoters of CIITA.     
Once CIITA is created, it serves as a coactivator with a few other 
transcription factors necessary for appropriate MHC-II regulation: RFX5, RFX-
AP, RFX-ANK, the NF-Y complex, and cAMP Response Element-Binding protein 
(CREB). RFX5, RFX-AP, and RFX-ANK are components of the greater RFX 
complex which binds the X1-box region of the MHC II promoter, while NF-Y 
factors binds the Y region and CREB binds the X2 region (Zhu, et al., 2000) 
(Figure 2). The assembly of these pieces creates an “enhanceosome” to which 
the CIITA binds and activates gene transcription of the MHC class II. Previous 
work by Steimle et al has also shown that transfection with CIITA cDNA can 
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render a cell constitutively class II positive (Steimle, Otten, Zuffarey, & Mach, 
1993). 
The Immune Response to the MHC 
The MHC is a very polymorphic region of the genome and different MHC 
molecules and classes (A, B, C) can differ by only a few amino acid substitutions. 
In allotransplantation, MHC-mismatched recipients can produce a humoral 
antibody-mediated response that can lead to rapid, hyperacute rejection. This 
occurs in “sensitized” patients that contain antibodies specific for foreign MHC as 
a consequence of prior exposure during pregnancy, blood transfusions, or 
allografting. A 
foreign MHC is 
any MHC 
structure that 
differs from the 
self-MHC found 
on autologous cells. Non-MHC antibodies can also occur when a recipient is 
exposed to antigens such as those on a bacteria or a foreign sugar, as is the 
case when an A- or O-blood type is transfused with B-blood type Red Blood Cells 
(RBCs) covered in the B-antigen. These bound antibodies activate the 
complement cascade resulting in cell damage or death. The occurrence of this 
complement cascade within the vessels of an allo- or xenograft, covered in MHC 
class I, results in hyperacute rejection (Dalmasso, et al., 1992). A similar process 
found in xenotransplantation when a baboon recipient recognizes αGal sugars on 
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the surface of the pig xenografts. De novo antibody production, following 
exposure to the transplanted organ, can also cause problems for grafts.  In 
allotransplantation the de novo production of antibodies to MHC class II results in 
late-stage AMR and transplant glomerulopathy (Willicombe, et al., 2012). 
Similarities Between SLA and HLA 
Using the National Center for Biotechnology Information Blast Alignment 
Search Tool to compare the protein sequences of HLA (DRB1*03, -DQB1*02, -
DRA*01:01:01:01, and –DQA1*01:01:01) to SLA (DRB1*0403, -DQB1*0303, -
DRA*w04e01, and –DQA*0204), revealed over 75% identity between the two 
species. The HLA genes were chosen because they are common in the human 
population and the SLA types are those found in Indiana University (IU) 
Xenotransplant Lab swine:  (Reyes, et al., 2014). These similarities suggest that 
anti-HLA antibodies could cross-react with SLA and II (Varela, Mozo, Cortes, 
Blanco, & Canedo, 2003). Additionally, future recipients may have previously 
created SLA-specific antibodies and TCRs through previous exposure to pig 
particles, either through diet (Hartig, Haller, Sachs, Kuhlenschmidt, & Heeger, 
2000) or vaccination (Kumar, et al., 2013). Although previous studies have 
shown human antibody binding to porcine tissue or cells, no reliable reagents 
exist for xenotransplant patient screening compared to allotransplantation.  
Tools to Measure the Immune Response 
To prevent rejection of donor grafts, recipients are tested for the presence 
of donor-specific antibodies (DSAbs). One of these tests, the cellular crossmatch, 
involves incubating recipient sera with donor cells and adding rabbit complement. 
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If DSAbs are present in the recipient sera, they activate complement, causing 
lysis of donor cells. Additionally, recipient sera can be tested against a 
representative panel of individual HLA alleles. Antibody binding to specific alleles 
in this panel allows us to determine what HLA-specific antibodies the potential 
recipient possesses. We can then calculate the number of positive results and 
express this as a percentage referred to a Panel Reactive Antibody (PRA). The 
PRA provides an estimate of how sensitized the recipient is to HLA molecules.  
Finally, sera can be incubated with beads coupled to various HLA alleles and 
analyzed by flow cytometry to observe the level of antibody binding to beads 
(Mulley & Kanellis, 2011). An adaptation of this used in xenotransplantation, the 
Flow Cytometry CrossMatch (FCXM), involves incubating sera on cells with a 
target antigen, staining the cells for antibody binding of IgM and IgG, and running 
the cells on flow cytometry. These tools can help determine what, if any, 
antibodies are present in potential recipients so grafts can be matched with the 
recipient least likely of rejecting the organ. Possessing a close match decreases 
the likelihood of graft rejection, as the recipient will not reject HLA types found in 
the body (Terasaki & Ozawa, 2004). 
Determining Antibody Binding to Class I or Class II 
An assay exists to determine the prevalence of anti-SLA class I antibodies 
in patient sera by performing a FCXM comparing SLA class I deficient PBMCs to 
PBMCs from a class I intact pig. If the antibody binding is higher on class I intact 
versus deficient cell, it is suspected those are anti-class I antibodies. 
Unfortunately, a reliable assay to determine the antibody and cellular response to 
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SLA class II does not exist: a SLA class II deficient pig does not exist, the assays 
in existence for class II rely on swine PBMC whose phenotypic makeup is not 
fully characterized (for example, both T and B-cells in swine contain class II 
MHC).  Adherent cell models utilize either cells expressing reduced levels of 
class II MHC as a consequence of expressing a dominant negative variant of 
CIITA. IFN-y is used to stimulate class II production in some assays, but 
expression can vary widely. 
The CRISPR/Cas9 System 
In recent years, scientists have used the type II clustered regularly 
interspersed short palindromic repeat (CRISPR) system and Streptococcus 
pyogenes CRISPR-Associated (Cas) protein to manipulate the eukaryotic 
genome. In the endogenous state, the bacterium first incorporates DNA from 
invading plasmids and viruses into the CRISPR locus amongst a period of short 
20 bp long palindromic repeats. The incorporated DNA and palindromic repeat 
will eventually serve as the Pre-CRISPR RNA (pre-crRNA). The pre-crRNA will 
be bound by a Transactivating crRNA (tracrRNA), and processed into CRISPR 
RNA (crRNA) by RNAase III. The tracrRNA:crRNA complex recruits the Cas9 
nuclease and the tracrRNA:crRNA:Cas9 complex then binds a DNA sequence 
that is both complementary to crRNA and capable of binding the Protospacer 
Adjacent Motif (PAM) found after the crRNA sequence. Following successful 
binding, the Cas9 generates a double-strand break in the DNA and the trimer 
complex unbinds. Repair mechanisms fixing these breaks are error prone, 
introducing mutations at a low frequency (Hsu, Lander, & Zhang, 2014).   
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The CRISPR-Cas9 system’s development as a genome editing tool took 
off in 2012 when the Doudna and Charpentier labs combined the tracrRNA and 
crRNA into a Single-Guide RNA (sgRNA). This advance allowed for a simple and 
rapid generation of plasmids that could efficiently mutate target DNA (Jinek, et 
al., 2012). 
Project Goals 
In order to develop an assay that determines whether SLA class II serves 
as a potential target for antibody binding three reagents needed to be created: 1) 
an II immortalized fibroblast cell line expressing class II SLA but lacking class I 
SLA; 2) SLA DR+ DQ-; and 3) SLA DR- DQ+ cell lines to further characterize the 
antibody preference to SLA class II. I hypothesized that there are antibodies 
capable of binding SLA class II, these antibodies are likely cross-reactive with 
HLA class II antibodies, and there is no preference to either subset of class II. If 
successful, this experiment will suggest SLA class II could be a potential 
antibody target in clinical xenotransplantation. 
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MATERIALS AND METHODS 
Culture of Parent Cell Line 
An SV40 T antigen immortalized fibroblast cell line derived from a SLA 
class I and galactose-α1,3-galactose (Gal) deficient pig was chosen as the 
parent cell line (Reyes, et al., 2014). The cells were confirmed to be Gal, SLA 
class I, class II negative by incubation with 
an isolectin Griffonia simplicifolia IB4 (IB4 
Lectin) Alexa Flour 647 (Invitrogen, Grand 
Island, NY, USA), an anti-SLA class I-FITC 
(AbD Serotec, Raleigh, NC), an anti-SLA 
class II DR-FITC (AbD Serotec, Raleigh, 
NC), and an anti-SLA class II DQ Ab (AbD 
Serotec, Raleigh, NC) and analysis using 
BD Accuri C6 Flow Cytometer (BD 
Biosciences, San Jose, CA) (Figure 3). 
These cells were cultured in Minimum 
Essential Media (MEM-α) (Invitrogen, Carlsbad, CA) supplemented with 10% 
Fetal Bovine Serum (FBS) (HyClone, Logan UT) in collagen-I-coated plates 
(Becton Dickinson, Bedford, MA) at 37°C, 5% CO2 and 10% O2. 
Transfection and Selection 
Cells were grown to 90% confluency in a 10-cm culture plate and 
transfected with Lipofectamine 2000CD (Invitrogen, Carlsbad, CA) as specified 
by company protocol. The donor plasmid, pCDNA3 myc CIITA (Plasmid #808) 
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was a gift from Matija Peterlin (Addgene plasmid #14650) (Kanazawa, Okamoto, 
& Peterlin, 2000) consisting of the human version of CIITA in a PCDNA3 plasmid 
backbone. Another CIITA plasmid, pCol2 flu CIITA, was tried in the cell line but 
failed to induce class II expression.  Differential promoter strength (CMV vs Col 
II) could explain the difference in the plasmids’ ability to induce class II. Three 
days post transfection cells were screened on a BD Accuri C6 Flow Cytometer 
(BD Biosciences, San Jose, CA) using a mouse anti-SLA class II DR-FITC Ab 
(AbD Serotec, Raleigh, NC). Cells with high levels of class II DR expression were 
sorted one cell per well into 96-well plates by the FACS Aria flow cytometer at 
the Indiana University (IU) Flow Cytometry Resource Facility. The cells were 
placed into selection using the antibiotic Geneticin, G418 (Invitrogen, Carlsbad, 
CA). Cells were cultured from the 96-well plate to individual 10-cm plates and 
analyzed for presence or absence of SLA class II DR using the previously 
mentioned anti-SLA class II DR antibody.	 Clones with a high level of SLA class II 
DR Ab binding were then evaluated for SLA class II DQ with mouse anti-pig SLA 
class II DQ (AbD Serotec, Raleigh, NC). Two clones were selected, one that 
demonstrated a class II positive DR(+)DQ(+) phenotype and another with a class 
II negative DR(-)DQ(-) phenotype, both resistant to G418 selection.  
	Sequencing 
DNA sequencing analysis of the MHC class II+ cell line was performed 
with genomic DNA isolated with the GenElute Mammalian Genomic DNA 
Miniprep Kit (Sigma-Aldrich, St. Louis, MO, USA). Reverse-transcriptase 
Polymerase Chain Reaction (RT-PCR) amplification of the class II alleles was 
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performed using the primers and conditions described by Reyes et al (Reyes, et 
al., 2014) and the RT-PCR products were sent for Sanger sequencing to 
Genewiz, Inc (Genewiz Inc., South Plainfield, NJ). 
Human Antibody Binding for Class II 
Sera samples were obtained from 183 patients on the IU transplant waitlist 
patients with IRB-approval. These samples were heat inactivated at 57°C for 30 
min and the sera was absorbed for 30 minutes on 50% packed WT pig RBCs to 
reduce background binding by removing any pig-specific non-MHC antibodies. 
12.5 uL of absorbed sera was incubated for 30 min at 4°C with 1 x 105 cells in 
EX-CELL 610-HSF Serum-Free Medium (Sigma, St. Louis, MO, USA) with 0.1% 
sodium azide on either the class II positive or negative cell lines. Cells were 
washed three times with EX-CELL + sodium azide and then stained with goat 
anti-human IgG Alexa Fluor 647 and donkey anti-human IgM Alexa Flour 647 
(Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA) for 30 min 
at 4°C. Cells were washed three times using EX-CELL medium as above and 
flow cytometric analysis was completed on BD Accuri C6 flow cytometer. 
Generation of sgRNA CRISPR/Cas9 Vectors 
Oligonucleotide pairs for the targeted sites in SLA class II DR and DQ 
were annealed to generate short double-strand DNA fragments with BbsI 
compatible overhangs. These fragments were then ligated into a BbsI digest 
pX330 plasmid. The chosen oligonucleotides used to construct the sgRNA 
expression vectors targeting class II are as follows: targeting exon 1 of the DQB1 
chain forward 5’-TGTCTGGGATGGTGGCTCTG-3’ and reverse 5’-
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CAGAGCCACCATCCCAGACA-3’; targeting exon two of DRB1 forward 5’-
GGAGCAGAAGCGGGCGGAGG-3’ and reverse 5’-
CCTCCGCCCGCTTCTGCTCC-3’; targeting exon two of DQA forward 5’-
GGCTGTCAATCAGGTTCCTG-3’ and reverse 5’-
CAGGAACCTGATTGACAGCC-3’; targeting exon two of DRA forward 5’-
TGCACTGGCCAACATAGCTG-3’ and reverse 5’-
CAGCTATGTTGGCCAGTGCA-3’ (Figure 4). pX330, a bicistrionic expression 
vector containing both the Cas9 gene and the BbsI cut site was purchased from 
Addgene (Plasmid #42230, http://www.addgene.org/42230/). 
Generation of DR(+)DQ(-) and DR(-)DQ(+) Cells 
The DR(+)DQ(+) was cotransfected with either the two plasmids described 
above targeting the beta chain or the two plasmids targeting the alpha chains. 
For this transfection, the Neon transfection system (Life Technologies, Grand 
Island, NY, USA) was used according to manufacturer’s instructions and 2 μg 
each plasmid was used. The cells transfected with the plasmids targeting the 
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class II alpha chain were sorted by the IU Flow Cytometry Resource Facility 
based on the absence of DR and presence of DQ, as determined by the 
monoclonal antibodies described above. The cells transfected with the plasmids 
targeting the class II beta chain were sorted for DR expression and absence of 
DQ, as determined by the monoclonal antibodies described above. 
Human Antibody Binding for DR or DQ 
Sera samples were obtained from 44 patients on the IU transplant waitlist 
patients with IRB-approval. 12.5 uL of absorbed sera was incubated for 30 min at 
4°C with 1 x 105 cells in EX-CELL 610-HSF Serum-Free Medium (Sigma, St. 
Louis, MO, USA) with 0.1% sodium azide on either the class II DR(+)DQ(+), the 
DR(+) DQ(-), the DR(-)DQ(+), or the DR(-)DQ(+) parent cell lines. Cells were 
washed three times with EX-CELL + sodium azide and then stained with goat 
anti-human IgG Alexa Fluor 647 (Jackson ImmunoResearch Laboratoies Inc., 
West Grove, PA, USA) for 30 min at 4°C. Cells were washed three times using 
EX-CELL medium as above and flow cytometric analysis was completed on BD 
Accuri C6 flow cytometer. 
Statistical Analysis of Binding 
Antibody binding results were reported as Median Fluorescence Intensity 
(MFI) of the FL4 channel. Graph and data analyses were completed using Prism 
6 for Macintosh (GraphPad Software Inc., La Jolla, CA, USA). Of the 183 
samples for the class II positive and negative FCXM, 122 samples were easily 
categorized into two groups based on the presence or absence of anti-HLA class 
II antibodies and used for statistical analysis. The 44 samples used for the 
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DR(+)DQ(-) and DR(-)DQ(+) FCXM were also analyzed for the anti-HLA class II 
sensitization but only three samples were found to have anti-HLA class II 
antibodies, not enough for a reliable statistical comparison. Human serum 
antibody binding assays were analyzed using a two-tailed paired or unpaired t-
test comparing single MFI results for each individual with significance set at p < 
0.05.  
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RESULTS 
Development of a Class II 
Positive and Negative Clone 
Integration of the human 
class II transactivator (CIITA) gene 
into a porcine fibroblast cell line 
successfully drove expression of 
both SLA DR and DQ, swine do not 
contain SLA-DP genes. Phenotypic 
staining of the parent cell line and 
resulting clones is shown in Figure 
5.  
Sequencing Results 
The MHC background of the parent pig was previously described by 
Reyes et al (Reyes, et al., 2014). As expected, the class II+ cell line expressed 
transcripts from all 
present alleles: 
DQA*0101, DQA*0204, 
DQB*0303, DQB1*0601, 
DRA1*020102, 
DRA*w04re01, 
DRB*0403, and 
DRB1*1001 (Figure 6).  
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Antibody Binding to SLA Class II Positive and Negative Cells 
Cells lacking 
expression of SLA 
class II 
demonstrated 
decreased IgG 
binding compared to 
cells with 100% SLA 
class II DR and DQ 
expression (Figure 
7) with no difference 
in IgM. A two-way 
paired t-test revealed statistical difference in total sera binding between a positive 
and negative cell for IgG (p = 0.0059) but not IgM (p = 0.2460). The antibody 
binding to a class II+ cell versus a class II- cell varies among sera: some 
individuals possess large quantities of antibodies capable of binding SLA class II 
and others possess almost none.  
Anti-HLA Class II Sera Antibody Binding 
122 of the 183 total patients screened in this study had accessible anti-
HLA class II antibody data. Of these samples with known anti- HLA antibody 
type, 60 (49%) were found to have anti-HLA class II antibodies and 62 (51%) 
were found to have no anti-HLA class II antibodies. Increased binding is found 
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when comparing those individuals with anti-HLA class II antibodies to those 
without (Figure 8). The difference in binding to the SLA class II positive cell was 
compared in a two-way unpaired t-test amongst individuals with and without anti-
HLA class II antibodies for IgG (p = 0.0229) and IgM (p = 0.3045).  
 
Development of DR(+)DQ(-) and DR(-)DQ(+) Cell Lines 
Transfection with CRISPR-Cas9 plasmids targeting either the alpha or 
beta chain of the class II molecule successfully generated DR(+)DQ(-) and 
DR(-)DQ(+) cell lines as depicted by the phenotypic staining in Figure 9. 
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	Antibody Binding to DR(+)DQ(-), DR(-)DQ(+), DR(+)DQ(+), and DR(-)DQ(-) 
Parent Cell Lines 
The results of the previous 
experiments revealed the importance of 
IgG analysis and subsequently only 
examined IgG for the class II subset 
FCXM. Statistical difference, as 
determined by a two-way paired t-test, 
was detected in the DR(+)DQ(-) vs. the 
DR(-)DQ(+) FCXM (p = 0.0099), the 
DR(+)DQ(-) vs. the DR(+)DQ(+) FCXM 
(p = 0.0192), and the DR(-)DQ(-) parent 
vs. DR(+)DQ(+) FCXM (p = 0.0329). No difference was found in the DR(-)DQ(+) 
vs. DR(+)DQ(+) FCXM (p = 0.1601). Binding patterns are depicted in Figure 10. 
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DISCUSSION 
Following successful elimination of the swine surface glycans, and in an 
effort to develop even less immunogenic xenografts, focus will turn to potential 
protein xenoantigens: the MHC. The MHC is one of the chief sources of rejection 
in clinical allotransplantation and the relationship between donor-specific 
antibodies (DSAbs) to MHC and graft rejection is well-documented (Ponticelli, 
2012). Numerous groups have also reported on the negative effect of HLA-
mismatches and graft survival (Duquesnoy, et al., 2003). The results of the 183 
sera FCXM study suggest that the swine MHC has the potential to contribute to 
the human anti-pig humoral xenogenic response. Additionally, the genetically 
conserved nature of the MHC across species, specifically the MHC class II, and 
the statistically significant difference in binding to SLA class II for individuals with 
anti-HLA class II antibodies, suggest that an antibody cross-reactivity exists 
between human leukocyte antigen HLA and SLA class II. If correct, future 
patients will need to be screened for both antibodies specific for SLA as well as 
anti-HLA antibodies capable of binding SLA.  
Furthermore, the development of DR(+)DQ(-) and DR(-)DQ(+) cell lines 
allowed for the evaluation of what, if either, subset of class II results in the 
stronger immune response. Surprisingly, the lack of statistical difference between 
DR(-)DQ(+) and DR(+)DQ(+) imply that SLA class II DQ will be the more 
immunogenic group. This perhaps makes sense, given the history of cross-
reactive groups (CREGs) and HLA’s role in allotransplantation. To briefly 
summarize, a CREG is an antibody that is capable of recognizing an amino acid 
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at a particular position in the HLA molecule. If other polymorphic HLA molecules 
possess that exact positional amino acid group, the CREG antibody is capable of 
binding, and therefore an antibody can “cross-react” across numbers of MHC 
molecules. Of the 21 known cross-reactive groups (CREGs) to HLA DQB, 10 are 
also found in SLA DQB (47.6%). Of the 60 known CREGs to HLA DRB, 11 are 
found in the SLA DRB (18.3%). The higher percentage of cross-species DQB 
CREGs means that of individuals with antibodies to HLA DQ, these antibodies 
are likely to also bind SLA DQ.   
In conclusion, this project resulted in the successful development an 
immortalized cell line that can be used for analysis of the role that SLA class II 
plays a role as a xenoantigen. This cell was used to demonstrate the existence of 
human-anti-pig antibodies, a possible anti-HLA/anti-SLA cross-reactivity, and the 
relative strength of SLA DQ as a target of antibody binding. Future studies will 
involve evaluating SLA class II as a target of T-cell response and to what extent 
this lymphocyte proliferation is due to cross-reactivity between HLA-specific 
TCRs and SLA class II. Finally, further inquiry is required to characterize the 
allelic patterns of xenoimmunogenic reactivity.  
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